Relay Therapeutics Inc logo

RLAY - Relay Therapeutics Inc Share Price

$37.39 -2.6  -6.5%

Last Trade - 05/03/21

Large Cap
Market Cap £2.59bn
Enterprise Value £2.08bn
Revenue £n/a
Position in Universe 1629th / 6647
Unlock RLAY Revenue
Relative Strength (%)
1m -21.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 36.7 8.75
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, RelayTherapeutics Inc revenues was not reported. Net losstotaled to $87.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RLAY Revenue Unlock RLAY Revenue

Net Income

RLAY Net Income Unlock RLAY Revenue

Normalised EPS

RLAY Normalised EPS Unlock RLAY Revenue

PE Ratio Range

RLAY PE Ratio Range Unlock RLAY Revenue

Dividend Yield Range

RLAY Dividend Yield Range Unlock RLAY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RLAY EPS Forecasts Unlock RLAY Revenue
Profile Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. The Company is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-1971 and RLY-4008, as well as its PI3Kα mutant selective program (RLY-PI3K1047 program). Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008 is designed to be an oral, small molecule, selective inhibitor of fibroblast growth factor receptor two (FGFR2), a receptor tyrosine kinase that is frequently altered in certain cancers

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated May 4, 2015
No. of Shareholders: n/a
No. of Employees: 132
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 89,984,775
Free Float (0.0%)
Eligible for
RLAY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RLAY
Upcoming Events for RLAY
Frequently Asked Questions for Relay Therapeutics Inc
What is the Relay Therapeutics Inc share price?

As of 05/03/21, shares in Relay Therapeutics Inc are trading at $37.39, giving the company a market capitalisation of £2.59bn. This share price information is delayed by 15 minutes.

How has the Relay Therapeutics Inc share price performed this year?

Shares in Relay Therapeutics Inc are currently trading at $37.39 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Relay Therapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Relay Therapeutics Inc?

There are no analysts currently covering Relay Therapeutics Inc.

When will Relay Therapeutics Inc next release its financial results?

Relay Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Relay Therapeutics Inc dividend yield?

Relay Therapeutics Inc does not currently pay a dividend.

Does Relay Therapeutics Inc pay a dividend?

Relay Therapeutics Inc does not currently pay a dividend.

When does Relay Therapeutics Inc next pay dividends?

Relay Therapeutics Inc does not currently pay a dividend.

How do I buy Relay Therapeutics Inc shares?

To buy shares in Relay Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Relay Therapeutics Inc?

Shares in Relay Therapeutics Inc are currently trading at $37.39, giving the company a market capitalisation of £2.59bn.

Where are Relay Therapeutics Inc shares listed? Where are Relay Therapeutics Inc shares listed?

Here are the trading details for Relay Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: RLAY
What kind of share is Relay Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Relay Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Relay Therapeutics Inc share price forecast 2021?

Shares in Relay Therapeutics Inc are currently priced at $37.39. At that level they are trading at 47.04% discount to the analyst consensus target price of 0.00.

Analysts covering Relay Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.12 for the next financial year.

How can I tell whether the Relay Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Relay Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -1.27%. At the current price of $37.39, shares in Relay Therapeutics Inc are trading at -7.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Relay Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Relay Therapeutics Inc.

Who are the key directors of Relay Therapeutics Inc?

Relay Therapeutics Inc's management team is headed by:

Sanjiv Patel - PRE
Donald Bergstrom - EVP
Brian Adams - GCN
Tom Catinazzo - VFN
Alexis Borisy - IND
Linda Hill - IND
Christoph Lengauer - IND
Mark Murcko - DRC
Douglas Ingram - IND
Who are the major shareholders of Relay Therapeutics Inc?

Here are the top five shareholders of Relay Therapeutics Inc based on the size of their shareholding:

SB Investment Advisers (UK) Limited Investment Advisor
Percentage owned: 31.01% (27.9m shares)
Third Rock Ventures, LLC Venture Capital
Percentage owned: 14.85% (13.4m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 5.26% (4.74m shares)
Casdin Capital, LLC Hedge Fund
Percentage owned: 4.23% (3.81m shares)
EcoR1 Capital, LLC Hedge Fund
Percentage owned: 3.56% (3.20m shares)
Similar to RLAY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.